leisure time -WSS

leisure time

author：leisure time 2025-10-02 17:27:34 - browse：86

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Generate Biomedicines machine learning biotech raises $273M

WSS

Long Covid needs a new name — and a new frame

FDA approves updated Covid vaccines

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Ascension's ugly legal battle over care for poor patients in Texas

WATCH: Why do bright lights make us see spots?

Medicare Advantage coverage denials need scrutiny, senators say

focus

leisure time

leisure time

In Memoriam: Notable people who died in 2023

New weight loss drugs vying to be the next Wegovy or Mounjaro

What does generative AI mean for health care? We asked experts

How medical schools plan to diversify without affirmative action

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA early review: GLP

Bright Health sells Medicare Advantage business to Molina

Fauci's latest grilling in Congress: 9 hours, behind closed doors

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

hotspot

Telehealth for opioid use disorder is lifesaving

Regeneron agrees to White House price limits on anti

STAT Virtual Event: JPM Recap, Live!

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Food makers to regulators: Ultra

Wikipedia

hotspot

focus

hotspot